Recently added

Non-renounceable Entitlement Offer – Extension of Closing Date

Non-renounceable Entitlement Offer – Extension of Closing Date

MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company) refers to its announcement titled ‘Non-renounceable Entitlement Offer’ dated 7 March 2023 in relation to the pro rata nonrenounceable entitlement offer to existing eligible shareholders to raise up to $2.4 million through the offer of one (1) new fully paid ordinary shares in the Company for every eight (8) shares held by eligible shareholders registered at 10 March 2023 at an issue price of $0.017 per share (Offer).

Capitalised terms used in this announcement but not defined have the meaning given to them in the Offer Document released to ASX on 7 March 2023, unless the context requires otherwise.

The Company advises that the Closing Date for the Offer has been extended to 14 April 2023.

The revised indicative timetable for the Offer is set out below.

* The above dates are indicative only and subject to change. The Company reserves the right, subject to the Corporations Act and the Listing Rules, to further change the Closing Date or to withdraw the Offer at any time without prior notice, in which case all Application Monies will be refunded (without interest) as soon as practicable. Any extension of the Closing Date will have a consequential effect on the issue date of New Shares. All dates and times are references to Melbourne, Australia time.

Applications for New Shares under the Offer may only be made by following instructions on the Entitlement & Acceptance Form which has been made accessible online to Eligible Shareholders. Shareholders eligible to participate in the Offer should read the Offer Document carefully and consult their professional advisers as necessary.

About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

Authorisation & Additional information
This announcement was authorised by the Board of Directors of Imagion Biosystems Limited

Related Articles

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.